De-Kuan Chang

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Dana-Farber-Cancer Institute Inc., The Brigham and Women's Hospital, Inc.. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: De-Kuan Chang. Retrieved from https://idiyas.com/inventor/de-kuan-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Malden, MA (US) (2016 - 2017)
Boston, MA (US) (2019 - 2023)

Company Filing History:

6 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

2 out of 1,428

The Brigham and Women's Hospital, Inc.

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12337034 - Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof (2025-06-24),

2. 11723973 - Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof (2023-08-15),

3. 10675349 - Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof (2020-06-09),

4. 10463732 - Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof (2019-11-05),

5. 9587028 - Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use (2017-03-07),

6. 9441045 - Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use (2016-09-13),

Title: The Innovations of De-Kuan Chang

Introduction

De-Kuan Chang is a prominent inventor based in Boston, MA, known for his significant contributions to the field of biomedical research. He holds a total of six patents, showcasing his innovative approach to developing therapeutic solutions.

Latest Patents

One of his latest patents is focused on humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof. This invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. The antibody is derived from CCR4-IgG1 and recognizes the same epitope. It contains either an IgG4 or a stabilized IgG4 to improve binding efficiency and reduce in vivo Fab arm exchange. The binding of these antibodies to CCR4 inhibits ligand-mediated activities and is utilized to treat symptoms of cancer.

Career Highlights

Throughout his career, De-Kuan Chang has worked with esteemed institutions such as Dana-Farber Cancer Institute Inc. and Brigham and Women's Hospital, Inc. His work has significantly impacted cancer research and treatment methodologies.

Collaborations

De-Kuan Chang has collaborated with notable colleagues, including Wayne A. Marasco and Quan Zhu, further enhancing the scope and impact of his research.

Conclusion

De-Kuan Chang's innovative work in developing humanized antibodies represents a significant advancement in cancer treatment. His contributions continue to influence the biomedical field and offer hope for improved therapeutic options.

Profile summary based on public USPTO records.